Takeda and TiGenix Report New Data Highlighting Maintenance of Long-Term Remission of Complex Perianal Fistulas in Crohn´s Disease Patients with Cx601 (TiGenix NV)
(WorldNews Belgium)

(Source: TiGenix NV) Takeda and TiGenix Report New Data Highlighting Maintenance of Long-Term Remission of Complex Perianal Fistulas in Crohn`s Disease Patients with Cx601 52-week results of the Phase 3 ADMIRE-CD trial presented at the 12thCongress of the European Crohn`s and Colitis Organisation (ECCO) Osaka, Japan, February 17, 2017, and Leuven, Belgium, February 17, 2017, 9:01 am CET - Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") and TiGenix NV (Euronext Brussels and Nasdaq: TIG) ("TiGenix") today announced new data from the Phase 3 ADMIRE-CD clinical trial, which indicated that investigational compound Cx601, a suspension of allogeneic adipose-derived...